The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.

The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York State approval as part of the permitting process.

Financial and other terms of the deal were not disclosed.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage ...

The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.

NEW YORK — The Scottish government has earmarked £800,000 ($1.1 million) to support the introduction of a Genedrive test to help prevent antibiotic-induced deafness in newborns within the country, ...

According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.

Last week, readers were most interested in a story about WHO's update to its operational handbook for diagnosing tuberculosis.

NEW YORK – BioMérieux announced Monday that it has obtained an expanded claim from the US Food and Drug Administration as well as CLIA waiver for its Respiratory/Sore Throat (R/ST) Panel Mini SpotFire ...

The organization noted that US senators have introduced a bill to accelerate Medicare coverage for breakthrough devices.

NEW YORK – Lumos Diagnostics announced Monday that it has completed a clinical trial of its FebriDx test and submitted it to the US Food and Drug Administration for CLIA waiver. If granted, the waiver ...

The MMR IHC Panel PharmaDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.